Revenue and operating profit grew strongly in 4Q 2025, with net profit surging on affiliate gains. Health supplement and holding segments showed robust performance, while pharmaceutical faced headwinds from delayed product launches.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.